Cargando…

Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555607/ https://www.ncbi.nlm.nih.gov/pubmed/31231564 http://dx.doi.org/10.1136/esmoopen-2017-000299corr1

Ejemplares similares

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case
por: Martinelli, Erika, et al.
Publicado: (2018)

HER2 Status in RAS and BRAF Wild-Type Metastatic Colorectal Cancer: A Portuguese Study
por: Fraga, Teresa, et al.
Publicado: (2023)

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer
por: Khelwatty, Said A., et al.
Publicado: (2021)

HER-3 expression in HER-2-amplified breast carcinoma
por: Czopek, Jacek, et al.
Publicado: (2013)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
por: Hamilton, Erika, et al.
Publicado: (2013)

Correction: Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines
Publicado: (2020)

Correction: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma
por: Lièvre, Astrid, et al.
Publicado: (2018)

Correction: Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer
por: Shetty, Praveenkumar K., et al.
Publicado: (2012)

HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer
por: Nakamura, Yoshiaki, et al.
Publicado: (2019)

Correction: Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor
por: Hu, Zexi, et al.
Publicado: (2018)

Author Correction: Clinical Implications of Sub-grouping HER2 Positive Tumors by Amplicon Structure and Co-amplified Genes
por: Maoz, Myriam, et al.
Publicado: (2020)

Metastatic, Her-2 Amplified Lacrimal Gland Carcinoma with Response to Lapatinib Treatment
por: Dennie, Trevor
Publicado: (2015)

Correction: HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
por: Gijsen, Merel, et al.
Publicado: (2016)

Correction: A Case of HER2 Mutated Colorectal Cancer Treated Successfully With Fam-Trastuzumab Deruxtecan
por: Reddy, Aswanth, et al.
Publicado: (2023)

RAS-expanded Mutations and HER2 Expression in Metastatic Colorectal Cancer: A New Step of Precision Medicine
por: Valentini, Anna M., et al.
Publicado: (2018)

A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients
por: Elez, Elena, et al.
Publicado: (2019)

Readministration of Cancer Drugs in a Patient with Chemorefractory Metastatic Colorectal Cancer
por: Kawagoe, Tetsuro, et al.
Publicado: (2020)

Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers
por: Campbell, Marcia R., et al.
Publicado: (2022)

Author Correction: The landscape of d16HER2 splice variant expression across HER2-positive cancers
por: Volpi, Chiara Costanza, et al.
Publicado: (2020)

Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?
por: Ricci, Angela Dalia, et al.
Publicado: (2021)

A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer
por: Kim, Tae Won, et al.
Publicado: (2016)

Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models
por: Belli, Valentina, et al.
Publicado: (2019)

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
por: Jacot, William, et al.
Publicado: (2019)

Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
por: Verschoor, Noortje, et al.
Publicado: (2023)

Correction: Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2020)

Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors
por: Floros, Konstantinos V., et al.
Publicado: (2021)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani, Pooja, et al.
Publicado: (2015)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
por: Adam-Artigues, Anna, et al.
Publicado: (2022)

Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
por: Yang, Liu, et al.
Publicado: (2022)

Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer
por: Geva, Ravit, et al.
Publicado: (2013)

Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
por: Jiménez-Fonseca, P., et al.
Publicado: (2014)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
por: Cheong, E. Von, et al.
Publicado: (2021)

Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
por: Maron, Steven B., et al.
Publicado: (2023)

Correction: Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells
por: Ma, Jui-Wen, et al.
Publicado: (2019)

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
por: Brasó-Maristany, Fara, et al.
Publicado: (2020)

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
por: Punturi, Nindo B., et al.
Publicado: (2021)

The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2
por: Saavedra Santa Gadea, Omar, et al.
Publicado: (2017)

Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
por: McDermott, Martina S. J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f49lb0pmqdnhde37ubfkf95uam